Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4D-125 in X-Linked Retinitis Pigmentosa
NCT04517149Phase 2Active, not recruiting
- Sponsor
- 4D Molecular Therapeutics
- Start
- Jun 2020
- Primary completion
- Jun 2026
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of 4D-125 in X-linked retinitis pigmentosa (XLRP), sponsored by 4D Molecular Therapeutics. Started Jun 2020; status: active, not recruiting.
02
Drugs
4D-125
03
Conditions
X-linked retinitis pigmentosa (XLRP)
Beyond the preview
Go deeper on NCT04517149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04517149.